Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PenniestoStacks, great research. Here is just a little information on the TIME Organization.
T I M E Organization Inc.
TIME Organization is a community-based Outpatient Mental Health Clinic, serving Baltimore City, Anne Arundel County and all surrounding counties. Our goal is to provide age and culturally appropriate services to all individuals by professionals who are credentialed and privileged. Moreover, it is the mission of TIME Organization to coordinate with other organizations when needed to offer and ensure that our clientele receives collaborative services from a treatment team that shares the common goal of recovery.
Time Organization is a licensed Outpatient Mental Health Center (OMHC) providing community based mental health services, substance abuse, services and multitude of other mental health and substance abuse related service. We are celebrating 16 years of service delivery and we are very excited to expand our services to our new location in:
Glen Burnie at 7310 Ritchie Highway Suite 100, Glen Burnie, MD 21061.
All of our staff are committed to providing mental health services with a community based and integrated model. Our staff is comprised of:
• Licensed social workers
• Licensed professional counselors
• Mental health clinicians
• Substance Abuse counselors
• Rehabilitation Specialists
• Rehabilitation Counselors
• Therapeutic Behavioral Aides
• Board Approved Clinical Supervisors
What investors need to understand, is that this gets Univec and the Univec Cannabis Transdermal Patch into the V.A. network of product suppliers. We are on our way folks. I expect news on this development soon.
The TIME Orgainziation is completely veteran owned.
Kgem
I agree DamAcon. The restructuring moved MariMed from being a real estate management and consulting firm to that of a cultivator and processor of hemp related products. CBD appears to be the primary focus right now, but there are many products that can be produced from hemp. I suspect the next phase will be to become a distributor as well.
I must say I am happy with my investment in MRMD. When I bought in here the stock was having a hard time holding $3.00, and hardly anyone was posting. I suggested the 30% buy-in stake in GenCanna was huge because it will bring in enormous revenue, and in my opinion, it is revenue that will drive share prices upward. I still hold that belief.
Kgem
Junebug, the importance of CARF accreditation cannot be overstated --- this is huge people. Why? Because CBD or Cannabidiol, with the exception of the new epilepsy treatment, is not considered a medicinal drug and as a supplement, it is not regulated by the FDA. This means CARF accreditation is literally the holly grail for anyone involved in the cannabis industry.
Good Morning Folks. For those who do not know and do not fully understand, CARF certification is huge. Doctor Dalton has been working on this certification for at least the last six months, and only now has this been approved. This may make UNVC the first cannabis related stock to ever attain such a high certification.
So what does CARF mean? CARF certification is very similar to FDA approval, and will likely be the stepping stone toward that eventual goal. CARF certification means insurance companies will cover the treatments, and for those who cannot afford the treatments, assistance can be provided. What I can safely tell you is that this is only the beginning.
Kgem
Yes Piedpiper, and we are also going into a three day weekend. People don't seem to like holding on to stocks over the weekend these days because they don't know if negative news will come out. I personally don't see any negative news, but one never knows.
Unvctrader, I don't think Doctor Dalton is being that specific, but I do like that thought. The fact is, we don't know how big Univec could become. We can speculate about multiple corporate partnerships and joint ventures that certainly could be worth millions and millions of dollars, a cure or treatment for major ailments like PTSD and Opioid addiction likely means government contracts, and I think we can look at other small companies that obtained government contracts and see what happened to them and to their stock price.
I looked at the LinkedIn message Doctor Dalton posted, and I must admit it does sound encouraging. I also reviewed the press release put out by MariMed, and I suspect any reasonable individual would have to admit that it does fit nicely with what Doctor Dalton says he is doing. Like others, I too would like to see the promised financials, but I think we have to consider what would likely be in those financials that should not be disclosed until everything is signed and sealed.
The first thing that comes to mind is the partnership to develop the Univec cannabis transdermal patch would have to be described along with the potential target market. Both these topics are material information, and they would need to be described and explained. In addition, any payment either to Dalton or from Dalton to other business entities would also have to be listed. The problem with these disclosures (which currently are not necessary for a non-reporting company) is that they could reveal information that might jeopardize current plans and negotiations. Frustrating to say the least, but understandable.
Like everyone else, I sure would like to see more information, but our only recourse is to buy or sell based on our own research and convictions.
Meanwhile, if Dalton is successful, the potential gains for even small time penny stock investors is astronomical. The choice is yours.
Captart, I agree.
Piedpiper, you make a very good point, and I will say that I do agree. I hope our CEO is under promising and then over delivering, but hope is not a good tactic for investing. I have looked deeply into GenCanna, and when you do your own due diligence, I think you will agree that it is a true gold mine. But I am open to discuss the matter. I will also admit that I have been mistaken in the past and could be again. Time will tell.
Piedpiper, I agree it is extraordinary, but do some research on GenCanna and their worldwide market before just writing off his remarks. In my opinion, the CEO is NOT exaggerating about the potential revenues. I guess we will all soon see, but I am betting he is actually being conservative.
Piedpiper, I think that revenue event is coming. This GenCanna deal is huge and I believe it will not only more than pay for itself, I also think it will provide funds to purchase even a higher percentage of GenCanna.
I agree vinsterr, all very good points.
PALM BEACH, Florida, January 17, 2019 /PRNewswire/ --
Financialnewsmedia.com News Commentary
It is proving more and more that Cannabis based companies must think and act beyond the current day-to-day operations as well as focus on product development, strategic partnerships and gaining consumer trust. Especially as the rising demand of marijuana for recreational use and medical use is a key factor driving massive growth potentials. In fact, legal cannabis and the rising popularity of CBD infused products has started gaining traction worldwide due to very high demand among consumers and increasing legalization of recreational or medical marijuana in various countries. According to Grand View Research, the global legal marijuana market is expected to reach USD $146.4 billion by end of 2025. Grand View also believes that an increasing number of companies operating in the marijuana market are expected to bolster the quantity and variety of products reaching the end users. Advances in new product development are expected to enhance product adoption among consumers while the legal marijuana market is witnessing strong technological and information exchange.
MariMed Inc. (OTCQB:MRMD) closed up over 6% at $3.80 on Wednesday by the market close. The company a leading multi-state cannabis operator, yesterday announced the formation of MariMed Hemp, Inc., a wholly-owned subsidiary to be entirely focused on hemp-derived CBD products. MariMed Hemp will have a dedicated executive team, proprietary brand and product lines, and distribution and marketing relationships, all separate from MariMed's core cannabis business.
The subsidiary builds on MariMed's recent investment in GenCanna Global, a leader in high-quality, fully compliant hemp cultivation and processing which is acclaimed for its genetics, proprietary cultivation practices and best in class processing procedures that produce world class, GMP, quality CBD isolates and oils. GenCanna anticipates planting and processing over 10,000 acres of hemp in 2019, making it one of the nation's largest hemp producers and the key supplier of hemp CBD oil to MariMed Hemp.
"With the recent signing of the U.S. Farm Bill that declared hemp fully legal at the federal level, we believe the hemp CBD industry may grow even faster than the cannabis industry," said Robert Fireman, CEO of MariMed. "Consumers and retailers alike seek the highest quality, trustworthy products. While many niche players may try to compete, the reality is that only a handful of suppliers can reliably deliver top-quality CBD products at scale that can serve the needs of major retailers."
https://www.bizjournals.com/prnewswire/press_releases/2019/01/17/enUK201901174835
Thank you vinsterr. Very encouraging post. We should talk sometime about Univec, AGRiMED, Sativeo, HCI and their various links to other companies.
I agree Piedpiper, MariMed has been on a roller coaster, as has the rest of the market. In MariMed's case, I think it mostly is because they spent so much money on growing the business in the last few months. Now, we should start seeing that money pay off starting on the next earnings report. In my opinion, earnings and revenue will drive the share price going forward. BTW, if you listen to his Bloomberg radio interview (only a few minutes long), I got the impression his comments might be on the conservative side. I also think we should soon hear something about plans to move to a higher exchange.
Piedpiper4, the comments regarding the revenue is from the Bloomberg radio interview cited on the news release informing investors of the new subsidiary called MariMed Hemp Inc. The news release appears to be from today.
Once MRMD consolidates their properties, the CEO claims they will have revenue of between 50 to 100 million dollars --- this is starting to sound like big money folks. MRMD is changing their business model from that of a consultancy and real estate management company to an actual grower and processor.
It sure is quiet on this board, but here is a little news. If anyone lives in Florida, this would be interesting to attend.
MariMed to be Featured at Benzinga Cannabis Capital Conference Jan 16th
January 10, 2019 08:34 ET | Source: MariMed Inc
Fireman, CEO of 2018 Top Performing Cannabis Stock in Mass., will share insight on MariMed, U.S. cannabis market opportunity
Norwood, MA and MIAMI, Jan. 10, 2019 (GLOBE NEWSWIRE) -- MariMed Inc. (OTCQB: MRMD) CEO Robert Fireman will be a featured presenter at the second annual Cannabis Capital Conference, hosted by premier financial media outlet Benzinga, to be held in Miami, Florida, Jan. 15-16, 2019. This highly-anticipated event sets the standard among cannabis conferences, offering unparalleled access and seamless interaction between the entrepreneurs who are establishing highly promising companies and the investors whose capital will fuel their efforts.
Fireman’s MariMed presentation will be at 1:50 pm in Ballroom 3 at Eden Roc Hotel-Miami Beach, 4525 Collins Avenue, Miami Beach, Fla. Mr. Fireman, who grew MariMed from its early stages to a multi-state, publicly traded cannabis organization that was one of the top performing cannabis stocks of 2018, will be in good company with presenters including top investors like CNBC's Tim Seymour, Jon Najarian and New Cannabis Ventures founder Alan Brochstein and other top cannabis company CEOs.
“2018 was a banner year for MariMed and the cannabis and hemp industries. In anticipation of the federal government legalizing hemp through passage of the 2018 Farm Bill, MariMed expanded its footprint into the Hemp CBD industry, creating a new business division and revenue stream,” stated Robert Fireman. “Several new medical and recreational cannabis markets have emerged or expanded this year. We’re looking forward to sharing details of strategic license and facility acquisitions and how we will leverage developments in new legal markets to accelerate MariMed’s growth in 2019 and beyond.”
Tickets for the Benzinga Cannabis Capital Conference are on sale now and can be purchased online at https://www.benzingacannabisconference.com. Investors can qualify for free passes by emailing bzcannabis@benzinga.com.
MariMed was named The Best Performing Stock in Massachusetts by the Boston Business Journal, The Best Performing Marijuana Stock in 2018 by Fresh Toast, one of the 3 Best Cannabis Stocks of 2018 by Motley Fool, and one of five Top Cannabis Stocks to Watch by High Times. MariMed has developed and manages six facilities in five states, has five additional facilities under development, and distributes its branded products in seven states.
Fireman will present an overview of MariMed’s current operations, examples of MariMed’s best-in-class branded products, an update of company strategy, and highlights of the company’s financial performance. His presentation will address MariMed’s competitive advantages in the US cannabis market, as well as a preview of emerging themes in the rapidly evolving U.S. cannabis industry.
Search MariMed and post on social media with the hash tag
#MedicatedByMarimed:
Twitter: @MariMedInc
Facebook: @MariMedInc
Instagram: MariMedInc
YouTube: MariMedInc
https://globenewswire.com/news-release/2019/01/10/1686159/0/en/MariMed-to-be-Featured-at-Benzinga-Cannabis-Capital-Conference-Jan-16th.html
Wingtrade, I called the company so no link to provide. MariMed is still interested in the grow or cultivation license and the two dispensaries, but nothing has been sold yet. The deal could still go through, is all I could get out of them. The grow facility is hydroponic and was set up to grow marijuana. Originally, 25 million was allocated for the grow facility, but only a fraction of that amount was ever spent because medical use turned to CBD and hemp instead of marijuana.
beerbreath, I have not personally seen the Univec cannabis transdermal patch, but as usual, you are asking the wrong question. The question should be have healthcare providers, clinics, and hospitals seen and tested the Univec cannabis transdermal patch, and I have been told they have and that is reason why we hear that big pharma has interest.
If Doctor Dalton prevails, the Univec transdermal patch will be the solution the Federal government is looking for.
Green Thumb signs $80M deal to acquire Connecticut medical marijuana firm
Published 44 mins ago
Green Thumb Industries (GTI), a vertically integrated, multistate cannabis company, signed a definitive agreement to acquire Connecticut’s Advanced Grow Labs in a deal valued at roughly $80 million.
Advanced Grow Labs, one of only four licensed medical marijuana cultivation and processing companies in the state, owns a 41,000-square-foot manufacturing facility in West Haven and a 46% stake in a not-yet-opened dispensary in Westport.
When the deal closes, Chicago-based GTI will have 12 manufacturing facilities and licenses for 85 retail shops in 11 states.
GTI went public in Canada in June via a reverse takeover and trades on the Canadian Securities Exchange under the ticker symbol GTII.
The company saw revenues increase 344% to $17.2 million in the third quarter.
Under the transaction, GTI will pay:
• $15 million in cash and 7 million subordinate voting shares of GTI stock.
• Up to an additional 1 million subordinate voting shares of GTI, subject to pricing conditions before closing.
• Additional considerations based on performance targets.
https://mjbizdaily.com/green-thumb-industries...aignId=625
Good job Wrenchman. Excellent due diligence.
Agreed.
Piedpiper I don't doubt that you are controlling the closing price, and I thank you for that. Stocks in general are closing lower because of trade fears, the Fed, the inability of Congress to do what is best for the country, and on and on. In the end, revenue will rule the day and that is all I am saying. I do read your posts nearly every day, but I have nothing to add at the present time. I suspect others are doing the same.
I think the long term outlook for MariMed looks good, but the short term is anyone's guess. It turns out the deal to buy AGRiMED was not as big as expected, and really only involved the purchase of a couple of dispensaries which never did happen. In my opinion, the GenCanna buy is huge, and will play out as increased revenue in the future. The revenue from dispensaries in Massachusetts is also huge. So, since stock price is typically dependent on revenue, I see continued long term share price appreciation. The weakness in the market with all the wild swings is hurting nearly everyone right now. Maybe human beings will once again work the trading floor and black boxes will be scraped, but I will not hold my breath waiting for that to happen.
MariMed entered into purchase agreements to acquire 100% ownership of AgriMed Industries, a licensed cannabis cultivation and production company in Pennsylvania, and KPG of Anna LLC and KPG of Harrisburg LLC, two cannabis-licensed MariMed clients that operate medical marijuana dispensaries in Illinois. These transactions are subject to approval by their respective states’ regulatory bodies.
“As we transition to owning the cannabis facility and business licenses, pending regulatory approval of the purchase transactions initiated in the third quarter of 2018, we will be consolidating all aspects of these entities – revenue, expenses, assets, liabilities, etc. – into MariMed financial reporting after completion,” stated Jon Levine, MariMed CFO. “Investors will see significant increases in each of these areas.
https://mjobserver.com/investments/marimed-reports-third-quarter-2018-financial-results/
I still have not seen where Pennsylvania approved the sale of these licenses. Has anyone else heard anything?
GenCanna (30% owned by MariMed) contracted with about a dozen Kentucky farmers in 2018 to grow hemp on 900-plus acres (364 hectares). In 2019 GenCanna plans to contract with more than 50 Kentucky farmers with a goal of more than 10,000 acres (4,047 hectares) of hemp production. To put this into perspective for MRMD investors, one square mile is equal to approximately 640 square acres. So MRMD's hemp farms can truly be measured by the square mile.
GenCanna is the first hemp company to be certified Kosher. GenCanna received kosher certification for all of its hemp-derived products from Kentucky Kosher International. GenCanna, which produces industrial hemp to form the bulk ingredient in lozenges, cannabidiol powder, tinctures and capsules, is based in Kentucky.
Newton Cohen, GenCanna’s director of external affairs, said the kosher certification attests the quality of the product for health conscious communities outside of the Jewish world.
https://jewishjournal.com/news/los_angeles/community/232940/first-hemp-company-certified-kosher/
Sooth Sayer, I don't think they expect to gain much from AGRiMED's grow facility itself. Instead, I suspect they are after an entry into the Pennsylvania market which is lucrative. Now what we don't know is what else comes with this purchase. MRMD now has some kind of relationship with AGRiMED and Univec, so could there be further developments? We will not know until we see a PR.
Sooth Sayer, I think you found a good one and at a very good price.
The Farm Bill should ignite explosive growth in the hemp market
Hemp is anticipated to be legal to grow across the United States beginning on Jan. 1, 2019. This has huge implications for the cannabis industry because hemp can be used to extract cannabidiol (CBD), a chemical found in the cannabis plant that has been associated with a wide range of medical and wellness benefits.
Given the massive growth projections for hemp, some forward-looking cannabis companies that have been focused on marijuana have recently been positioning themselves to profit from the U.S. hemp market. One such company is MariMed (NASDAQOTH: MRMD).
On Tuesday and Wednesday, the U.S. Senate and House of Representatives, respectively, overwhelmingly passed the latest version of the 2018 Farm Bill, which contains provisions that would make it legal on a federal level to grow industrial hemp. President Trump is widely expected to sign the bill by year's end, with the effective date likely Jan 1, 2019.
If the current Farm Bill becomes law, the U.S. market for hemp is projected to explode. Relevant to cannabis investors, the U.S. hemp-derived CBD market is expected to balloon by about 37 times in just four years, according to cannabis research firm Brightfield Group. That firm expects the market to grow from about $591 million in annual revenue this year to $22 billion by 2022.
MariMed, based in the Boston area, is a multistate cannabis company that develops, owns, and manages cannabis cultivating and processing facilities as well as branded product lines.
In the third quarter, MariMed's revenue soared 98% year over year to $3.4 million. According to its earnings release, this growth was driven by increased rental income from its facilities in Maryland and Massachusetts, higher revenue from cannabis supply procurement services, and increased "management fees and additional rental revenue ... [from] its cannabis-licensed clients." Operating income rocketed 200% to $861,000, the net loss widened 2,500% to $10.2 million, and the loss per share came in at $0.05, versus $0.00 in the year-ago quarter.
The fact that MariMed generated a profit on an operating basis is more than nearly all other cannabis companies can say. MariMed's net loss widened because, like nearly all players in the cannabis space, it's investing heavily in growth initiatives. The company ended the quarter with $6 million in cash. Given its annual cash burn rate of $19.9 million through the end of the third quarter, its cash position is the first thing investors should be monitoring.
https://finance.yahoo.com/news/hemp-verge-u-legalization-could-005400182.html
I fully understand your position Piedpiper, and I do not blame you for taking a profit whenever one has one. What I see is MRMD is currently in both the lucrative Massachusetts and New Jersey markets which are booming according to most reports. MRMD is gaining a major foothold in the CBD market nationally and even internationally. The passage of the Farm Bill is soon to be signed and that is expected to be a major shot in the arm for this industry. The Vitiprints technology just finished its testing phase and is now ready for market. The purchase of the Pennsylvania grow facility from AGRiMED gains MRMD access to the Pennsylvania market once regulators sign off and, they are trying to enter the Florida market as well. So for me, entering the New Year looks pretty good. But, I am not a short term in and out type of investor.
Piedpiper, stocks go up and stocks go down --- sometimes for no reason at all. When I look at the performance of MRMD, and the number of markets they are entering, I see nothing but growth for this company. So for me, this is a great buying opportunity. However, for those looking for a quick in and out flip, no so much so.
MariMed Positioned to be Leader in Hemp CBD Era with 2018 Farm Bill Signing Imminent
December 14, 2018 08:05 ET | Source: MariMed Inc
NORWOOD, MA, Dec. 14, 2018 (GLOBE NEWSWIRE) -- As President Trump prepares to sign the 2018 Farm Bill into law in coming days, MariMed, Inc. (OTCQB: MRMD), a leading cannabis operator that recently announced a major hemp investment, hailed the imminent signing of the bill as “the official launch of the Hemp CBD Era.”
“The expected signing of the Farm Bill will enable Americans to enjoy legal access to a host of hemp-derived CBD-based solutions, which are already renowned for their health and wellness benefits, ,” said Robert Fireman, MariMed CEO. “MariMed expects to make a series of Hemp CBD product and distribution announcements in 2019. We are excited about the potential of legalized hemp to benefit millions of Americans in many ways.”
MariMed has made a significant commitment to the rapidly-growing, hemp-derived CBD product industry, which analysts project growing to $22 billion globally by 2022, from today’s estimated $800 million. In November, MariMed announced its $30 million investment and strategic partnership in a leading agriculture and technology company specializing in the production of hemp-derived CBD.
Hemp-derived CBD has been shown to reduce anxiety, depression and sleep disorders without the side effects and addiction risks of many pharmaceuticals. CBD has also been proven effective in treating a wide range of medical conditions, including certain types of epilepsy, some cancers and painful cancer treatments, arthritic and muscular pain, high blood pressure, and various skin conditions, including acne.
“With restrictions on hemp research likely to lift, MariMed is beginning to collaborate with researchers to develop more effective delivery mechanisms and product options for specific medical, health and beauty treatments,” said Fireman.
Charles Finnie, MariMed Chief Strategy Officer, noted, “Hemp will be an important, eco-friendly, drought-resistant crop that creates abundant jobs and tax revenue. It is time for hemp to assume its rightful place as a cornerstone agricultural crop that has the power to reshape America’s health and wellness landscape.”
About MariMed Inc.:
MariMed is a multi-state cannabis company that develops, owns and operates licensed cannabis facilities and develops and distributes branded cannabis and hemp product lines. MariMed’s team has developed state-of-the-art regulatory-compliant facilities in DE, IL, NV, MD, MA, and RI, which are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. In addition, MariMed is on the forefront of precision-dosed branded cannabis and hemp-derived products for the treatment of specific medical conditions. MariMed currently distributes its branded products in approximately 10 states, and is expanding licensing and distribution to additional markets, encompassing thousands of dispensaries and additional retail outlets. MariMed Inc. is one of the top-performing public cannabis companies in the U.S., according to the U.S. Marijuana Index, (www.marijuanaindex.com) and Boston Business Journal named MariMed the top performing stock in Massachusetts.
https://globenewswire.com/news-release/2018/12/14/1667270/0/en/MariMed-Positioned-to-be-Leader-in-Hemp-CBD-Era-with-2018-Farm-Bill-Signing-Imminent.html
Wingtrade, not really. All I see right now (a press release should clear up the confusion) is that the grow and processing facility located in Pennsylvania was acquired by MRMD. This facility is no longer important for Univec, because we are getting our CBD from Sativeo which is located in South Carolina. The purchase of the AGRiMED facility in PA gets rid of a headache for Sterling Crockett, and gains MRMD access to the Pennsylvania market. So, unless we hear otherwise, this is a good deal for all concerned. However, I suspect there is even more going on.
Give it a little time Piedpiper, we are just getting 8ks right now. From the news reports I am reading, the Massachusetts market is booming and the state of New Jersey just approved adult use. I expect revenue reports soon, but I fully expect MariMed to plow everything they get back into growing their business and expanding market share.
Demand For Cannabis Prompts Marimed To Expand CBD Hemp Operations
The cannabis industry is quickly turning into a multi-billion dollar powerhouse thanks to the drastic demand for cannabis products. Reports have it that cannabis revenues are likely to hit $9 billion by the end of the year. This kind of speculation has resulted in serious investment by various companies seeking to grab a share of the growing market. Marimed Inc. (OTCMKTS:MRMD) is one of those, which has chosen to enter the hemp-derived CBD business.
The Massachusetts-based cannabis operator has invested $30 million in a Kentucky company, GenCanna. The strategic partnership by the two companies will enhance the operations in the hemp CBD industry. Each of them has different capabilities and expertise.
Partnership presents expansion opportunities
MariMed is expecting to reap big from the investment and the primary goal is to expand its CBD hemp operations. Currently, the company operates in select states but it is seeking to incorporate additional markets. It is also worth noting that it is one of the 17 top-performing public cannabis companies in the United States.
The swift legalization of cannabis in various states presents remarkable opportunities for hemp and hemp-derived products. This is more reason that the partnership may yield results according to GenCanna’s CEO. Matty Mangone-Miranda says, “Our partnership with MariMed represents a major step toward harnessing the hemp market’s enormous potential.”
Anticipation of the passage of the Hemp Farming Act of 2018
GenCanna has established production processes, which are in line with Good Manufacturing Practices (GMP) standards. It works closely with consumer protection agencies and other regulatory bodies. MariMed has also developed state-of-the-art regulatory-compliant facilities to support its development strategies.
However, there is still a lot of anticipation of the passage of the Hemp Farming Act of 2018. The passage will not only open doors for hemp companies but also for federal banking and financial services. It will also give the business environment the ability to offer a wider range of products that cross numerous categories.
Meanwhile, GenCanna has vowed to continue building relationships with the bigger players of the hemp industry.
https://finance.yahoo.com/news/demand-cannabi...19203.html
MRMD at $3.75 a share is a great price for a company about to break to new highs. 8ks are being filed, and soon news will hit the wires.
Cannabis Companies Aggressively Expand Operations Heading Into 2019 to Meet Surging Consumer Demand
8:55 am ET December 6, 2018 (PR Newswire)
The demand for cannabis products is surging as the market rapidly evolves and turns into a multi-billion dollar powerhouse. Fueled by favorable political conditions including sweeping legalization, as well as the creation of new customers, cannabis has become one of the hottest commodities in the market. According to Marijuana Business Daily, legal cannabis revenues could end up reaching as high as $9 billion by year-end, which would illustrate a roughly 42% growth from last year's output. This drastic growth is forcing leaders in the industry to expand operations in order to keep up with demand and avoid product shortages. Leaders are investing in infrastructure, property, and new plant and equipment to maximize their operations.
https://invest.ameritrade.com/grid/p/site#r=jPage/https://research.ameritrade.com/grid/wwws/research/stocks/news/article?c_name=invest_VENDOR&docKey=100-340p7428-1